Reviews
27 May 2010
Featured Articles
https://doi.org/10.4081/jnai.1654

Survival of the fittest or best adapted: HLA-dependent tumor development

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Cancer, HLA, Ancestral Haplotypes, DNA, mRNA
5477
Views
720
Downloads
3528
HTML

Authors

Giuseppe V. Masucci
giuseppe.masucci@ki.se
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
Emilia Andersson
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
Lisa Villabona
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
Hildur Helgadottir
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
Kjell Bergfeldt
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Switzerland.
Federica Cavallo
Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
Guido Forni
Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
Soldano Ferrone
University of Pittsburgh Cancer Institute, Departments of Surgery, Immunology and Pathology, School of Medicine, Pittsburgh, PA, USA, United States Minor Outlying Islands.
Aniruddha Choudhury
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
Barbara Seliger
Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany, Germany.
Rolf Kiessling
Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
The major histocompatibility complex (MHC) comprises a set of genes that are critical to immunity and surveillance against neoplastic transformation. There is increasing evidence that the MHC antigens not only regulate antitumor immune responses in experimental animal models but directly correlate with survival and prognosis of patients with diverse types of cancers. MHC antigens may in the future function as potential biomarkers for prognosis and allow selection of cancer patients for intensive therapy.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

Cancer Society in Stockholm and Gustav 5th Jublilee fond, the motility grant #040226# from "NordForsk, Holbergs gate 1, NO-0166 Oslo, NORWAY" to the NCV

How to Cite



Survival of the fittest or best adapted: HLA-dependent tumor development. (2010). Journal of Nucleic Acids Investigation, e9. https://doi.org/10.4081/jnai.1654
Copyright (c) 2010 Giuseppe V. Masucci, Emilia Andersson, Lisa Villabona, Hildur Helgadottir, Kjell Bergfeldt, Federica Cavallo, Guido Forni, Soldano Ferrone, Aniruddha Choudhury, Barbara Seliger, Rolf Kiessling Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.